Article

Toric IOL gets FDA approval

The Tecnis toric 1-piece IOL (Abbott) has received FDA approval, and the company is launching the lens in the United States for treatment of cataract patients with pre-existing corneal astigmatism.

 

Abbott Park, IL-The Tecnis toric 1-piece IOL (Abbott) has received FDA approval, and the company is launching the lens in the United States for treatment of patients with cataract and pre-existing corneal astigmatism.

The toric 1-piece IOL remains very stable once inserted into the eye, and meets the new standard for toric IOL rotational stability, an important attribute of a toric IOL, as approved by the American National Standards Institute. In addition to providing astigmatism correction, the toric 1-piece lens minimizes spherical aberration to provide sharper distance vision for the patient.

“The . . . toric IOL decreases astigmatism while improving visual quality, with improved functional vision,” said Kevin Waltz, OD, MD, Eye Surgeons of Indiana, and clinical investigator for the Tecnis toric IOL. “Having implanted several . . . toric IOLs within clinical trials, I find it delivers excellent patient results.”

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 American Society of Cataract and Refractive Surgery (ASCRS) meeting, Seth Pantanelli, MD, speaks about the EyHance and enVista IOLs. Dr. Pantanelli is a professor of ophthalmology at Penn State College of Medicine in Hershey, Pennsylvania.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Kamran M. Riaz, MD, an expert on IOLs
Kamran M. Riaz, MD, an expert on IOLs
Kamran M. Riaz, MD, an expert on IOLs
Kamran M. Riaz, MD, an expert on IOLs
© 2025 MJH Life Sciences

All rights reserved.